SOT112 and SOT113 are next-generation bispecific ADCs against undisclosed targets, which SOTIO is developing for the treatment of solid tumors. Both programs are currently in preclinical development stage. With four different platform technologies available (NBE-Therapeutics, LigaChem Biosciences (formerly LegoChem), Synaffix, and Biocytogen), SOTIO is able to select and tailor the most suitable ADC technology and payloads for the needs of these particular targets in particular solid tumor indications.